Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anifrolumab - Bristol-Myers Squibb/MedImmune

Drug Profile

Anifrolumab - Bristol-Myers Squibb/MedImmune

Alternative Names: Anti-IFNaR MAb - Medarex/MedImmune; MDX-1333; MEDI-546

Latest Information Update: 22 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex
  • Developer Medarex; Medical University of Vienna; MedImmune
  • Class Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interferon alpha beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • Phase II Lupus nephritis; Rheumatoid arthritis
  • Discontinued Scleroderma

Most Recent Events

  • 28 Dec 2018 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus(In volunteers) in USA (SC, Infusion)
  • 17 Dec 2018 AstraZeneca completes a phase II trial in Systemic lupus erythematosus in USA, Poland, Hungary and South Korea (NCT02962960)
  • 27 Sep 2018 AstraZeneca completes the phase III TULIP 2 trial in Systemic lupus erythematosus in USA, Spain, Lithuania, Argentina, Belgium, Brazil, Bulgaria, Canada, Czech Republic, France, Germany, Japan, South Korea, Mexico, Russia, Singapore and South Africa (IV) (NCT02446899) (EudraCT2014-004632-19)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top